A New Molecular Mechanism To Engineer Protean Agonism at a G Protein–Coupled Receptor by De Min, Anna et al.
1521-0111/91/4/348–356$25.00 http://dx.doi.org/10.1124/mol.116.107276
MOLECULAR PHARMACOLOGY Mol Pharmacol 91:348–356, April 2017
Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics
A New Molecular Mechanism To Engineer Protean Agonism at a
G Protein–Coupled Receptor s
Anna De Min, Carlo Matera,1 Andreas Bock, Janine Holze, Jessica Kloeckner,
Mathias Muth, Christian Traenkle, Marco De Amici, Terry Kenakin, Ulrike Holzgrabe,
Clelia Dallanoce, Evi Kostenis, Klaus Mohr, and Ramona Schrage2
Pharmacology and Toxicology Section, Institute of Pharmacy (A.D.M., J.H., C.T., K.M., R.S.), Research Training Group
1873 (A.D.M., E.K., K.M.), and Molecular-, Cellular-, and Pharmacobiology Section, Institute of Pharmaceutical Biology (E.K.),
University of Bonn, Bonn, Germany; Dipartimento di Scienze Farmaceutiche, Sezione di Chimica Farmaceutica ‘Pietro Pratesi,’
Università degli Studi di Milano, Milano, Italy (C.M., M.D.A., C.D.); Institute of Pharmacology and Toxicology, University of
Würzburg, Würzburg, Germany (A.B.); Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University
of Würzburg, Würzburg, Germany (J.K., M.M., U.H.); and Department of Pharmacology, University of North Carolina School of
Medicine, Chapel Hill, North Carolina (T.K.)
Received October 24, 2016; accepted February 2, 2017
ABSTRACT
Protean agonists are of great pharmacological interest as their
behavior may change in magnitude and direction depending
on the constitutive activity of a receptor. Yet, this intriguing
phenomenon has been poorly described and understood, due
to the lack of stable experimental systems and design strate-
gies. In this study, we overcome both limitations: First, we
demonstrate that modulation of the ionic strength in a defined
experimental set-up allows for analysis of G protein–coupled
receptor activation in the absence and presence of a specific
amount of spontaneous receptor activity using the muscarinic
M2 acetylcholine receptor as a model. Second, we employ this
assay system to show that a dualsteric design principle, that is,
molecular probes, carrying two pharmacophores to simulta-
neously adopt orthosteric and allosteric topography within a G
protein–coupled receptor, may represent a novel approach to
achieve protean agonism. We pinpoint three molecular require-
ments within dualsteric compounds that elicit protean agonism
at the muscarinic M2 acetylcholine receptor. Using radioligand-
binding and functional assays, we posit that dynamic ligand
binding may be the mechanism underlying protean agonism of
dualsteric ligands. Our findings provide both new mechanistic
insights into the still enigmatic phenomenon of protean ago-
nism and a rationale for the design of such compounds for a G
protein–coupled receptor.
Introduction
G protein–coupled receptors (GPCRs) comprise the largest
superfamily of cell surface receptors, accounting for 3% of all
genes in the human genome (Fredriksson and Schiöth, 2005).
Upon activation, GPCRs undergo a global conformational
rearrangement to transduce their signals from extracellular
stimuli into the intracellular environment. Via this mecha-
nism, binding sites for cytosolic adaptor proteins, for instance
heterotrimeric G proteins, become exposed (Rasmussen, et al.,
2011; Kruse et al., 2013), which then serve to propagate the
signaling within the cell (Pierce et al., 2002; Lefkowitz, 2004).
GPCRs are versatile membrane proteins that exist in ensem-
bles of possible conformations (Manglik and Kobilka, 2014),
and ligands can be classified according to their ability to
stabilize subsets of these conformations (Rosenbaum et al.,
2009). For instance, agonists favor active receptor conforma-
tions over inactive states. Of note, receptors can also sponta-
neously transit from inactive to active states and vice versa
(Costa and Herz, 1989; Leff, 1995).
In addition to the binding site for the endogenous mes-
senger, GPCRs carry distinct druggable sites, which are
designated as allosteric sites. Compounds binding to these
allosteric binding sites may alter the efficacy and/or binding
affinity of orthosteric ligands but may also exhibit intrinsic
efficacy for receptor activation/inactivation in their own right
(Christopoulos, 2002). Allosteric modulation has extensively
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been studied atmuscarinic acetylcholine receptors (mAChRs),
which are prototypal class A (rhodopsin-like) GPCRs. Recent
studies have also described dualsteric ligands, which can
simultaneously occupy the orthosteric and an allosteric
binding site of the M2 subtype of mAChRs. This results in
a unique receptor-binding profile and signaling pattern
(Steinfeld et al., 2007; Gregory et al., 2010; Bock et al., 2012;
Schrage and Kostenis, 2016). Dualsteric/Bitopic ligands can
switch between two binding poses, that is, either a dualsteric
or a purely allosteric binding pose (Bock et al., 2014, 2016) and
thus may stabilize not only one but at least two distinct
subsets of receptor conformations (dynamic ligand binding)
(Bock et al., 2014).
A particularly fascinating, albeit seldom described, class of
GPCR ligands are protean agonists, that is, compounds that
display agonism in quiescent receptor systems with low levels
of spontaneous receptor activity and inverse agonism in
constitutively active systems (Kenakin, 1995). One explana-
tion for this phenomenon may be that protean agonists
stabilize a receptor conformation with lower efficacy for a
certain signaling pathway than the spontaneously active
conformation of a givenGPCR. Thus, even though the intrinsic
efficacy of the ligand does not vary, its effect changes with the
amount of spontaneously active receptors that are present
within the experimental system (Kenakin, 1995, 1997).
Up to now, protean agonists have only been identified for a
handful of receptors, for instance cannabinoid receptor 2 (Yao
et al., 2006; Mancini et al., 2009; Xu et al., 2010; Bolognini
et al., 2012), histamine receptor 3 (Gbahou et al., 2003), a-2A
adrenergic receptor (Jansson et al., 1998; Pauwels et al.,
2002), serotonin receptor 1B (Newman-Tancredi et al., 2003),
bradykinin receptor 2 (Fathy et al., 1999; Marie et al., 1999),
and b-2 adrenergic receptor (Chidiac et al., 1994, 1996).
Nevertheless, protean agonists are highly valuable tools, as
they might be most useful for the identification of ligand-
specific active states of GPCRs (Kenakin, 2001). Furthermore,
protean agonists may represent a promising new class of
pharmacologically active compounds in targeted drug therapy
for those cases in which receptor mutations cause constitutive
activity (Tao, 2008). Under these conditions, protean agonists
can re-establish the original tone of receptor activation
(Jansson et al., 1998; Mancini et al., 2009). Moreover, the
classification of ligands as protean agonists is of significant
importance and not trouble-free, because they may be mis-
taken for inverse agonists in in vitro assays with high levels of
constitutive activity (Chidiac et al., 1994), but act as agonists
in vivo (Yao et al., 2006; Mancini et al., 2009; Xu et al., 2010).
The rather few examples of GPCR protean agonists are, at
least in part, due to the lack of experimental systems in which
the amount of spontaneous GPCR activity is reliably and
reproducibly controlled. Moreover, specific design strategies
to generate protean ligands are missing. In this study, we
overcome both limitations: we have developed an assay
system to enable such control and employ it in this study to
demonstrate that the dualsteric design approachmay serve as
a novel means to rationally create protean agonists using
muscarinic acetylcholine receptor 2 (M2AChR) as a model
system.
In particular, we establish and validate experimental
conditions that permit analysis of M2 receptor–mediated Gi
protein activation, in the absence and presence of a defined
amount of spontaneous receptor activity. We found the
following: First, dualsteric ligands were able to induce protean
agonism at M2AChR. Second, we identified specific pharma-
cophoric elements that have to be combined to induce protean
agonism at this receptor subtype. Third, we propose that
dynamic ligand binding (Bock et al., 2014, 2016) may be the
underlying molecular mechanism of protean agonism of
dualsteric compounds targeting M2AChRs.
Therefore, our findings deliver a new experimental system
to study spontaneous activity of GPCRs, two new protean
agonists for M2AChR, and a new strategy along with a
potential molecular mechanism to achieve protean agonism
at this receptor subtype, which may pinpoint to the design of
protean agonists at other GPCRs.
Materials and Methods
Materials and Reagents. Acetylcholine (ACh) iodide, atropine
sulfate, and pilocarpine hydrochloride were obtained from Sigma-
Aldrich Chemie (Steinheim, Germany). Guanosine 59-O-(g-[35S]thio)-
triphosphate ([35S]GTPgS) and [3H]N-methylscopolamine bromide
([3H]NMS) were from PerkinElmer Life and Analytical Sciences
(Homburg,Germany).Cell culturemedia,HEPES,N-methyl-D-glucamine,
sodium bromide, bovine serumalbumin (BSA), GDP, and DL-dithiothreitol
(DTT) were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Magnesium chloride (MgCl) and sodium chloride (NaCl) were
acquired from Acros Organics (Geel, Belgium). Na2EDTA was pur-
chased from Applichem (Darmstadt, Germany). Tris(hydroxymethyl)-
aminomethane (Tris) and potassium chloride (KCl) were acquired from
Carl Roth (Karlsruhe, Germany).
Chemical Synthesis. The synthesis of all compounds that are
not commercially available has been performed following the proto-
cols described elsewhere: iperoxo (iper) (Klöckner et al., 2010); isox
and oxo-oxotremorine M (OOM) (Dallanoce et al., 1999); isox-6-
naphthalimide (naph) (Disingrini et al., 2006); isox-8-naph and 8-naph
(Bock et al., 2014); iper-6-naph, 6-naph, and 6-phthalimide (phth)
(Antony et al., 2009); iper-8-naph (Bock et al., 2012); isox-6-phth
(Disingrini et al., 2006); iper-6-phth (Antony et al., 2009); and OOM-6-
naph and OOM-6-phth (Disingrini et al., 2006). All derivatives were
obtained with comparable yields and the same analytical purity as
reported in the literature.
Cell Culture. Flp-In-Chinese hamster ovary (CHO) cells stably
expressing the human muscarinic acetylcholine M2 receptor (CHO-
hM2 cells) were cultured in Ham’s nutrient mixture F-12 (Ham’s F-12)
supplemented with 10% (v/v) fetal calf serum, 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine at 37°C in a 5% CO2
humidified incubator. The cells were passaged by trypsinization at
nearly confluence.
Membrane Preparation. CHO-hM2 cells were grown to 90%
confluence and treated with fresh medium supplemented with 5 mM
sodium butyrate for 18–20 hours. On the day of the membrane
preparation, medium was aspirated and 2.4 ml ice-cold harvesting
buffer (20 mM HEPES, 10 mM Na2EDTA, pH 7.4) was added. Cells
were mechanically detached with a cell scraper (Sarstedt AG,
Nümbrecht, Germany) before the cell suspension was homogenized
using a Polytron homogenizer (1  25 seconds and 1  20 seconds,
level 6). The suspension of lysed cells was centrifuged (10 minutes,
40,000  g, 2°C), and the pellet was resuspended in storage buffer
(20 mM HEPES, 0.1 mM Na2EDTA, pH 7.4). This centrifugation step
was repeated twice. The remaining pellet was resuspended in an
adequate amount of [35S]GTPgS assay buffer (50 mM Tris, 2 mM
MgCl, 1 mM Na2EDTA, 1 mM DTT, pH 7.4) and stored at 280°C
(Schrage et al., 2013).
Equilibrium-Binding Assays. To estimate apparent agonist-
binding affinities, membranes from CHO-hM2 cells were diluted in
assay buffer, that is, Tris buffer (50 mM Tris, 2 mM MgCl, 1 mM
Na2EDTA, 1 mMDTT, pH 7.4) or Tris NaCl buffer (50 mMTris, 2 mM
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MgCl, 1 mM Na2EDTA, 1 mM DTT, 200 mM NaCl pH 7.4),
supplemented with 100 mM GDP. A total of 30 mg/ml membrane
suspensions was then incubated with 0.2 nM [3H]NMS and different
concentrations of test compound in a 96-well microtiterplate (Thermo
Scientific ABgene, Schwerte, Germany) in assay buffer in a final
volume of 500 ml at 24°C for 3 hours to reach equilibrium conditions.
Experiments were terminated by rapid vacuum filtration using a
Tomtec Harvester (Tomtec, Hamden, CT), and filter-bound radioac-
tivity was calculated by solid scintillation. Nonspecific binding was
determined in the presence of 10 mM atropine.
Dissociation-Binding Assays. To estimate ligand affinity to the
allosteric binding site, [3H]NMS dissociation-binding assays were
conducted. A total of 30 mg/ml membranes was preincubated with
2 nM [3H]NMS in assay buffer [Tris or Tris NaCl buffer (see above)]
supplemented with 0.5% BSA and 1 mM GDP for 45 minutes at 24°C.
Net dissociation of [3H]NMS was initiated by the addition of 10 mM
atropine, with or without the indicated concentrations of test com-
pound. After the appropriate time interval (12 and 9 minutes in Tris,
and 6 and 3 minutes in Tris NaCl buffer), the dissociation was
terminated by rapid vacuum filtration with a Tomtec Harvester
(Tomtec) and filter-bound radioactivity was calculated by solid
scintillation. Nonspecific binding was defined as the radioactivity
bound in the presence of 10 mM atropine.
[35S]GTPgS-Binding Assay. A total of 40 mg/ml CHO-hM2
membranes was incubated with 0.07 nM [35S]GTPgS, 1 mM GDP,
0.5% BSA, and test compound in Tris buffer (50 mMTris, 2 mMMgCl,
1 mMNa2EDTA, 1 mMDTT, pH 7.4) or Tris NaCl buffer (50 mMTris,
2 mM MgCl, 1 mM Na2EDTA, 1 mM DTT, 200 mM NaCl, pH 7.4) for
60 minutes at 24°C. Experiments were terminated by rapid filtration
with a Tomtec Harvester (Tomtec), and filter-bound radioactivity was
measured by solid scintillation counting.
Data Analysis. Equilibrium-binding data were analyzed by a
four-parameter logistic equation (Barlow and Blake, 1989) yielding
IC50 values that were subsequently converted into apparent
equilibrium dissociation constants (KA) using the Cheng-Prusoff
correction (Cheng and Prusoff, 1973). Data from two-point kinetic
dissociation experiments were analyzed using a one-phase expo-
nential decay, as described elsewhere (Kostenis and Mohr, 1996,
Voigtländer et al., 2003). Data obtained from [35S]GPTgS-binding
assays were fitted to a four-parameter logistic equation yielding
measures for agonist potency [negative logarithm of the concen-
tration of test compound inducing a half maximum response
(pEC50)] and maximum effect (Emax). All nonlinear regression
analyses were performed using Prism 5.03 (GraphPad Software,
San Diego, CA).
Statistical Analyses. Shownaremeanvalues6S.E.M.Comparison
of two singlemeanswasperformedusing anunpaired two-sampleStudent
t test. In case the number of data setswas equal or superior to three, a one-
way analysis of variance test with Bonferroni’s post-test was used.
Results
Distinct Binding Poses of Dualsteric Ligands May
Result in Protean Agonism. To unravel potential protean
agonism at themuscarinicM2 receptor, we applied a variety of
orthosteric agonists, allosteric fragments, and dualsteric li-
gands (i.e., iper-6-naph, iper-8-naph, iper-6-phth, isox-6-naph,
isox-8-naph, isox-6-phth, OOM-6-naph, OOM-6-phth; Fig. 1A)
and investigated receptor-mediated activation of inhibitory Gi
proteins in [35S]GTPgS-binding experiments.
Fig. 1. Test compounds and proposed mechanism of action of dualsteric ligands acting as protean agonists. (A) Structures of the dualsteric ligands
examined in this study; their respective orthosteric moieties isox, iper, and OOM; and the allosteric fragments C6-naph, C6-phth, and C8-naph. The
classic muscarinic partial agonist pilocarpine and the endogenous agonist AChwere used as reference compounds. (B) Proposedmodel to clarify themode
of action of dualsteric protean agonists at the M2 receptor. Dualsteric ligands may potentially bind either in a dualsteric binding pose, stimulating
receptor signaling, or in a purely allosteric pose, inactivating the receptor (Bock et al., 2014). In this sense, dualsteric binding of protean agonistsmay lead
to a positive signaling output in an inactive receptor system (hypothetical blue curve), whereas the compound may behave as an inverse agonist in a
receptor system with spontaneous activity (hypothetical red curve).
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The dualsteric ligands tested in the present study consist of
an orthosteric part, that is, iper, isox, or OOM, and an
allosteric moiety, that is, either the naph or phth group. The
two pharmacophores are covalently connected via a hexa- or
octamethylene linker. The orthosteric building block provides
high affinity for interaction with the binding site of the
endogenous messenger, whereas the allosteric moiety has
affinity for the allosteric binding site, which is located on top of
the orthosteric site in the extracellular part of mAChRs (Prilla
et al., 2006; Bock et al., 2012; Haga et al., 2012). In consequence,
these bipharmacophoric ligands are able to bind in two orien-
tations to a receptor protein (Bock et al., 2014): either both
pharmacophores bind to their designated binding sites, yielding
a dualsteric binding pose, or the compound only interacts with
the allosteric site of the receptor, yielding a purely allosteric
binding pose (Bock et al., 2016) (Fig. 1B). As the allosteric
fragments are derived from allosteric antagonists/inverse ago-
nists, the purely allosteric binding pose stabilizes an inactive
receptor conformation (Tränkle et al., 1998; Disingrini et al.,
2006; Bock et al., 2014; Matera et al., 2014). In contrast, the
dualsteric binding pose stabilizes active receptor conformations,
because the orthosteric moieties are agonists (Dallanoce et al.,
1999; Schrage et al., 2013; Bock et al., 2014).
The unique ability of dualsteric compounds to bind in two
different binding poses leads to a potential scenario in which
these model derivatives may act as protean agonists because
the affinities of the two pharmacophores may change in
different systems (Bock et al., 2014). A dualsteric compound
that prefers binding in an allosteric binding topography will
result in inverse agonism in a system with pronounced
spontaneous receptor activity (red curve in lower panel of
Fig. 1B). However, if this compound is also able to bind in a
dualsteric binding pose, functional agonism may occur in a
quiescent receptor system (blue curve in lower panel of Fig.
1B). Thus, the versatile behavior of dualsteric ligands may be
an avenue toward the design of protean agonists.
Establishment of an Experimental System with a
Stable Amount of Constitutive Activity of the Muscarinic
M2 Receptor. The investigation of protean agonism is
technically challenging because it requires a stable, sponta-
neously active receptor system, which is difficult to achieve for
several GPCRs (Kenakin, 2001). To establish a system that
displays a robust and substantial amount of spontaneous
activity for the M2AChR, we investigated the M2 receptor–
mediated binding of [35S]GTPgS in CHO stably expressing the
muscarinic acetylcholine M2 receptor (CHO-M2) membranes
triggered by the endogenous agonist ACh or the inverse
agonist atropine in the presence of various concentrations of
NaCl in a Tris buffer. NaCl was chosen as a buffer supplement
because sodium ions are known to be important to maintain
the inactive receptor conformation of class A GPCRs (Liu
et al., 2012; Katritch et al., 2014;Miller-Gallacher et al., 2014).
In line with this, an increase of NaCl led to a reduction in basal
[35S]GTPgS binding to CHO-M2 membranes as well as to a
decrease in spontaneous receptor activity (estimated in pres-
ence of Atr) and ACh-induced [35S]GTPgS (Fig. 2Ai). To
explore whether alternative conditions with an ionic strength
equivalent to 200 mM NaCl may also be suitable to titrate
spontaneous activity of the M2AChR, we analyzed the effect of
the inverse agonist atropine sulfate on M2-mediated [
35S]GTPgS
binding in aTris bufferwith 2mMsodium ions (low ionic strength
Tris, Tris) in comparison with a Tris buffer substituted with
200 mM NaCl or equimolar concentrations of KCl, sodium
bromide, orN-methyl-D-glucamine chloride (NMDGCl). NMDGCl
is often used as a sodium substitute, as it was found to be
osmotically equivalent (Pihlavisto et al., 1998; Barann et al., 2004;
Billups et al., 2006;Vivo et al., 2006). Interestingly, any increase in
ionic strength led to a complete abolishment of spontaneous
receptor activity regardless of whether sodium or potassium salts
were applied, orNMDGClwas used as a substitute (Fig. 2Aii).We
conclude that conditions with an ionic strength equivalent to
200 mMNaCl may also serve to keep the receptor in the inactive
state.
Next, we were interested in the nature of the M2 receptor
system with high rates of spontaneous activity (low ionic
strength Tris, Tris) in comparison with a quiescent M2
receptor system (Tris supplemented with 200 mM NaCl, Tris
NaCl, or KCl, Tris KCl). We hypothesized that high sponta-
neous M2 activity may either do as follows: 1) increase the
basal level of [35S]GTPgS binding without altering the
maximum inducible effect of the system (Supplemental Fig.
1A) or 2) lead to an increase in basal [35S]GTPgS binding and
also a higher potential Emax of the system (Supplemental Fig.
1B). To approach these hypotheses experimentally, we mea-
sured [35S]GTPgS binding in CHO-M2membranes induced by
the endogenous agonist ACh (Fig. 2Bi) and the muscarinic
superagonist iper (Fig. 2Bii) in one system where the receptor
was spontaneously active (red,Tris) and two systemswhere no
spontaneous activity was apparent (light blue, Tris KCl, and
blue, Tris NaCl). In line with our hypothesis number two
(Supplemental Fig. 1B), both basal and ligand-induced re-
ceptor activity was enhanced in the spontaneously active
system. We next investigated [35S]GTPgS binding to CHO-
M2 membranes induced by five different orthosteric musca-
rinic agonists in a Tris NaCl buffer (Fig. 2Ci, quiescent
receptor) and a low ionic strength Tris buffer (Fig. 2Cii,
spontaneously active receptor). Agonists may prefer binding
to spontaneously active receptors as this enhances the prob-
ability of ternary complex formation of agonist, receptor, and
G protein (De Lean et al., 1980; Strange, 2008). Accordingly,
all muscarinic agonists displayed increased potency for M2
receptor activation in a low ionic strength Tris buffer (Fig. 2C,
i and ii; Supplemental Table 1), accompanied with higher
apparent agonist-binding affinities (Supplemental Fig. 2;
Supplemental Table 1).
Interestingly, iper shows a higher Emax value than ACh,
isox, and OOM. This might indicate a lower stimulus–
response coupling in the quiescent system, which enables to
directly visualize the higher efficacy of iper over the other
investigated agonists. Of note, the classical muscarinic partial
agonist pilocarpine is an exception to the observed trend, as
the Emax value and the potency did not change with the
spontaneous activity of the system.
Specific Dualsteric Compounds Display Protean
Agonism at Muscarinic M2 Receptors. The ability to
reliably fine-tune spontaneous M2 receptor activity enabled
us to investigate [35S]GTPgS binding in CHO-M2 membranes
induced by dualsteric compounds in a quiescent receptor
system (Tris NaCl) or a spontaneously active receptor system
(Tris). When the muscarinic superagonist iper was incorpo-
rated as the orthosteric part into the dualsteric ligand, the
three tested compounds behaved as agonists in both buffer
systems (Fig. 3, A–C). Iper-6-naph (Fig. 3A) and iper-6-phth
(Fig. 3B) displayed higher agonist efficacy and potency in the
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spontaneously active receptor system in comparison with the
quiescent receptor state, whereas iper-8-naph only slightly
gained potency in Tris buffer over Tris NaCl (Fig. 3C).
Conversely, when isox or OOM, which possess ACh-like
efficacy, was applied as orthosteric building blocks (Fig. 3, D–
H), the effect induced by isox-6-naph (Fig. 3D) andOOM-6-naph
(Fig. 3G) changed its direction, depending on the activity state
of the M2 receptor: in an inactive M2 receptor system, both
compounds behaved as partial agonists (blue), whereas in a
systemwith spontaneous activity of the receptor both displayed
inverse agonism (red), as expected for protean agonists. In
contrast to this and in line with the findings for iper-6-phth,
isox-6-phth (Fig. 3E) and OOM-6-phth (Fig. 3H) had increased
efficacy inTris buffer as comparedwithTrisNaCl. Likewise, we
noted higher efficacy for the isox-derived hybrid carrying an
allosteric naph residue with a linker length of 8 carbon atoms
(isox-8-naph) in the spontaneously active receptor system over
the quiescent system (Fig. 3F). As predicted and in agreement
with previous findings (Jäger et al., 2007; Antony et al., 2009;
Bock et al., 2014), the allosteric fragments 6-naph, 8-naph, and
6-phth (Fig. 1A) alone behaved as allosteric inverse agonists in
presence of high spontaneous M2 receptor activity but were
silent at the inactive receptor (Supplemental Fig. 3).
Taken together, our data allow us to derive structure–
activity relationships to induce protean agonism at musca-
rinic M2 receptors: the orthosteric agonist should display an
ACh-like efficacy for receptor activation; the allosteric residue
should be bulky—the sterically demanding 1,8-naph moiety
being superior to the less voluminous phth analog—and the
two pharmacophores should be connected by an alkyl chain of
optimally six carbon atoms.
Dissociation-Binding Experiments Point to an
Increased Allosteric Affinity to M2 Receptors in Tris
Buffer of a Protean Agonist. To assess whether protean
agonism of isox-6-naph and OOM-6-naph was due to an
increase in allosteric binding to the [3H]NMS-bound M2
receptor in the low ionic strength buffer, we estimated binding
affinities for selected compounds in the allosteric binding pose
to M2. To this end, [
3H]NMS dissociation experiments were
performed in a low ionic strength Tris buffer (red curve) and
Tris buffer supplemented with NaCl (blue curve) to measure
allosteric binding affinities in the same ionic strength than the
aforementioned [35S]GTPgS-binding experiments (Fig. 4).
Both investigated dualsteric compounds carrying iper as the
orthosteric building block, that is, iper-6-naph and iper-8-
naph, displayed a gain in affinity for allosteric binding (Fig. 4,
Fig. 2. Establishment of a robust assay
system with substantial amount of spontane-
ous activity for the muscarinic M2 receptor.
(Ai) Increasing concentrations of NaCl affect-
ing basal, atropine-inhibited, and ACh-induced
[35S]GTPgS binding. (Aii) Effect of NaCl, KCl,
sodiumbromide, orNMDGCl (200mMeach) on
the spontaneous activity of M2 receptors in
[35S]GTPgS experiments. ***P , 0.001, sig-
nificantly different from Tris according
to one-way analysis of variance test with
Bonferroni’s post-test. (B) Experimental
dose–response curves of (Bi) ACh and (Bii)
iper obtained in presence (Tris) or absence
(Tris NaCl, Tris KCl) of constitutive activity
of the M2 receptor. In the spontaneously
active system, thewhole curve was translated
to higher values, as proposed in Supplemen-
tal Fig. 1B. (C) Orthosteric compound-induced
[35S]GTPgS binding in CHO-hM2membranes
in absence (Tris NaCl, Ci) or presence (Tris,
Cii) of spontaneous receptor activity. Al-
though the maximum inducible effect (Emax)
of isox and OOM was equal to that of ACh in
both systems, iper showed a superior Emax
than ACh in a silent system. (A–C) Shown are
mean values 6 S.E.M. of three to seven
independent experiments, each performed in
triplicate.
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A and B; Supplemental Table 1) of ∼three- and sevenfold,
respectively, to M2 receptor in Tris compared with Tris NaCl
buffer. The protean agonist isox-6-naph displayed a greater
increase in affinity, of ∼20-fold (Fig. 4C; Supplemental
Table 1), in the low ionic strength over theNaCl supplemented
buffer. In contrast to this, the affinity for the allosteric binding
site of isox-8-naph appeared to be similar in both buffer
systems (Fig. 4D). The allosteric affinity of the OOM-
containing protean agonist OOM-6-naph was significantly
increased in Tris buffer in comparisonwith TrisNaCl (sixfold),
even though the gain in affinity was not as prominent as that
reported for isox-6-naph (Fig. 4E). Taken together, these data
indicate that both protean agonists may display increased
allosteric binding under the assay conditions similar to the
spontaneously active system compared with the conditions of
the inactive system and that thismay contribute to the inverse
agonism that we observed for isox-6-naph and OOM-6-naph.
Of note, we also observed an increase in allosteric binding for
iper-6-naph and iper-8-naph to the M2 receptor in Tris com-
pared with Tris NaCl, although these two compounds clearly
did not display any protean agonism. This might be explained
by the higher intrinsic efficacy for receptor activation of the
orthosteric moiety iper in comparison with isox and OOM. In
consequence, the beneficial effect of the spontaneously active
M2 receptor on the orthosteric superagonist iper (increase in
binding affinity 10-fold in Tris versus Tris NaCl) surpassed the
increase in allosteric binding (increase in allosteric binding
affinity 3.5-fold and sevenfold for iper-6-naph and iper-8-naph,
respectively), and this precluded protean agonism.
Discussion
Protean ligands induce opposing effects (Emax) depending on
the level of spontaneous activity of a GPCR. This phenomenon
Fig. 3. Isox-6-naph and OOM-6-naph display protean agonism in CHO-hM2 membranes in absence (Tris NaCl) or presence (Tris) of spontaneous
receptor activity. (A–C) Dualsteric ligands that carry iper as the orthosteric building block displayed partial agonism in both the silent and the
spontaneously active set-up regardless of their C6-naph (A), C6-phth (B), or C8-naph (C) allosteric moiety. Noteworthily, iper-6-naph and iper-6-phth
displayed significantly higher Emax values in the spontaneously active system. (D–H) Isox-6-naph, isox-6-phth, isox-8-naph, OOM-6-naph, and OOM-6-
phth were all weak partial agonists in the quiescent system (blue curve) but changed their Emax in the presence of constitutive receptor activity (red
curve). Isox-8-naph displayed increased receptor activation (F), isox-6-phth (E) and OOM-6-phth (H) showed no difference in effect, whereas the two
compounds with a C6-naph moiety, that is, isox-6-naph (D) and OOM-6-naph (G), switched from partial to inverse agonism and were thus classified as
protean ligands. (A–G) Shown are mean values 6 S.E.M. of three to seven independent experiments, each performed in triplicate.
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was first reported in 1995 (Kenakin, 1995) and is based on the
assumption that ligand-bound GPCRs may adopt not only one
(fully) active and one inactive conformation, but also intermedi-
ate conformations engendering intermediate intrinsic efficacies
for activation of intracellular signaling pathways. In this regard,
receptor species with a lower efficacy than the spontaneously
active one yield positive signaling in the presence of quiescent
receptors and negative signaling when the majority of receptors
is constitutively active (Kenakin, 1997, 2001; Chidiac, 2002).
Experimentally, the discovery of protean ligands remains chal-
lenging for two reasons, that is, the lack of the following: 1) stable
and reliable spontaneously active systems for several GPCRs
and 2) strategies for the rational design of this class of ligands.
In the present study, we show that spontaneous activity of
the muscarinic M2 receptor can reliably be titrated by changing
the ionic strength in CHO-M2 [
35S]GTPgS-binding experi-
ments. We used this system to identify dualsteric compounds
as protean agonists at M2AChR. Structure–activity relation-
ships allowed us to define the molecular features required for
protean agonism at M2 receptors among a set of dualsteric
compounds and to introduce a new molecular mechanism for
protean agonism.
In particular, we present two dualsteric ligands, that is,
isox-6-naph and OOM-6-naph, as new protean agonists at the
muscarinic M2 receptor. Interestingly, only slight alterations
of the three chemical moieties were sufficient to shift the
profile from protean agonism to classical agonism (Fig. 3).
The molecular features required for protean agonism at the
muscarinic M2 receptor are as follows: an orthosteric part
endowed with an acetylcholine-like efficacy, a bulky allosteric
part to impair the flexibility of the extracellular loop area, and
a flexible linker chain of six carbon atoms.
Up until now, protean agonism was thought to reside in the
intrinsic efficacy of a ligand (Kenakin, 1997). Our results point
to an additional mechanism that may underlie this phenome-
non at GPCRs in case a ligand can simultaneously occupy both
the binding site for the endogenousmessenger and an allosteric
binding site of the receptor protein. These dualsteric com-
pounds may bind to a receptor protein in two distinct binding
modes (Bock et al., 2014, 2016), a purely allosteric and a
dualsteric mode (Fig. 1B), and may thus have two distinct
efficacies for receptor activation. Our findings presented in this
work go in linewith the idea that the two protean agonists, isox-
6-naph andOOM-6-naph, prefer binding in the purely allosteric
binding pose, as has already been demonstrated for isox-6-naph
in a previous study (Bock et al., 2014). Both compounds display
functional inverse agonism under conditions in which the M2
receptor displays a substantial amount of spontaneous activity
(Fig. 3, D and G). However, at least under conditions in which
the receptor is silent, a significant fraction of receptors must be
bound in a dualsteric binding pose, as we observed functional
agonism in the quiescent M2 system. This indicates dynamic
ligand binding as themolecularmechanism of protean agonism
of isox-6-naph and OOM-6-naph.
Spontaneous activity of the M2AChR could robustly be fine-
tuned by changing the ionic strength of the applied buffer
system, such as presence/absence of sodium ions. To test
whether isox-6-naph and OOM-6-naph swap their binding
pose depending on the buffer system used, we performed
radioligand-binding experiments and estimated the allosteric
binding affinity (EC50,diss values) of several dualsteric ligands
included in this study. The allosteric affinity measure of isox-
6-naph was 20 times higher in Tris than in Tris NaCl buffer,
whereas the orthosteric building block isox gained only 3.5-
fold in affinity under these conditions (Fig. 4C; Supplemental
Fig. 2). Assuming that the affinities of the allosteric and of the
orthosteric moiety determine the fraction of ligand bound in
one or the other pose (Bock et al., 2014), this result supports
the idea that isox-6-naph increases in allosteric binding pose
in the low ionic strength buffer. Yet, OOM-6-naph displayed
only a slight increase in allosteric binding affinity in Tris
versus Tris NaCl buffer. This effect was comparable to the
increase in orthosteric affinity of the orthosteric building block
OOM. Even if these data indicate that OOM-6-naph does not
display increased allosteric binding in Tris buffer, the domi-
nant binding pose under these conditionsmust be the allosteric
pose, as we clearly see inverse agonism at the spontaneously
activeM2AChR (Fig. 3G). Of note, changes in the ionic strength
of the buffer may not only alter the spontaneous activity of the
M2AChR (see Fig. 2B, increase of the lower curve plateau), but
may also affect the microenvironment in the orthosteric and
Fig. 4. Isox-6-naph displayed enhanced affinity to the allosteric binding site
of the [3H]NMS-bound M2 receptor in Tris. (A–E) [
3H]NMS dissociation
experiments performed in presence of (A) iper-6-naph, (B) iper-8-naph,
(C) isox-6-naph, (D) isox-8-naph, and (E) OOM-6-naph in Tris or Tris
NaCl buffer. Depicted are concentration–effect curves that show the delay of
[3H]NMS dissociation rate (k-1) induced by the dualsteric test compounds
in two-point kinetic experiments (Kostenis and Mohr, 1996). The inflection
point of the curves represents the allosteric affinity of the tested compounds
for the [3H]NMS-bound receptor. (A–E) Shown are mean values6 S.E.M. of
three to five independent experiments, each performed in duplicate.
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allosteric binding pocket. Therefore, ligand-binding behavior
may be altered not only by the functional state of the receptor
protein, but additionally may be influenced by the presence/ab-
sence of ions in the binding pockets. Interestingly, all dualsteric
compounds share a common bis-ammonium alkane structure
that is known to engage with the allosteric M2AChR binding
site via polar cation–p interactions (Dror et al., 2013), which are
susceptible to variation of ionic strength (Papaneophytou et al.,
2014).
However, our study clearly indicates a major impact of ionic
strength on the macro level, that is, the functional state of the
receptor. A recent study by Yuan et al. (2016) has shown that a
continuous channel of water molecules inside the receptor
protein is an essential feature of the functionally active state
of the adenosine A1 receptor, another class A GPCR that most
likely shares a common activation mechanism with the
M2AChR. Therefore, one might speculate that ionic strength
fine-tunes receptor activity by determining the amount of
water molecules available within the binding pocket. Yet,
albeit tempting, ultimate proof for such a hypothesis remains
to be provided by crystallographic studies.
One might argue that protean agonism of isox-6-naph and
OOM-6-naph resides in the rather low efficacy of the two ligands
and is not necessarily due to dynamic ligand binding. However,
dualsteric ligands such as isox-6-phth and isox-8-naph did not
display any protean agonism, although the efficacy of these
compounds did not differ significantly from the efficacy of the
two protean agonists at the quiescentM2AChR.Moreover, it has
been demonstrated previously that a purely allosteric binding
pose predominates for isox-6-naph (Bock et al., 2014). In sum,
our data indicate that dynamic ligand binding (Bock et al., 2014)
is the underlying molecular mechanism for protean agonism of
isox-6-naph and OOM-6-naph at M2AChR.
Protean agonism is still a seldom described phenomenon.
Studies that identified protean agonists by comparison of
agonist-induced signaling in two different functional assay
systems may be compromised by biased signaling (Jansson
et al., 1998; Gbahou et al., 2003). Therefore, two experimental
systems that differ only in the amount of spontaneous activity
are essential for the identification of protean agonists. To this
end, several strategies have been employed to study agonism in
presence and absence of spontaneously active receptors. For
instance, constitutively activating receptor mutations (Ganguli
et al., 1998; Fathy et al., 1999; Pauwels et al., 2002), an
increased expression of receptor/G protein (Jakubík et al.,
1998), or a change in buffer composition (Newman-Tancredi
et al., 2003) have been applied. In this study, we chose to alter
M2 wild-type receptor activity by variation in the concentration
of sodium ions, because previous studies demonstrated that
sodium ions can keep class A GPCRs in an inactive conforma-
tion (Liu et al., 2012; Katritch et al., 2014). Yet, our results
indicate that inactivation of the M2AChR by a high concentra-
tion of sodium ions depends on high ionic strength in the buffer
rather than the nature and/or composition of a particular salt.
In a low ionic strength Tris buffer, basal as well as agonist-
induced [35S]GTPgS incorporation was increased in CHO-M2
membranes in comparison with a buffer system with high
concentrations of sodium or potassium ions. This is in line with
previous findings (Tian et al., 1994) for the adrenergic a2-AR
and reflects a stronger stimulus–response coupling and ternary
complex formation of agonist, receptor, and G protein of the
spontaneously active M2 receptor compared with quiescent M2.
Accordingly, the distinct efficacies of ACh and iper could only be
detected in the inactive receptor system (Fig. 2C). Moreover,
almost all dualsteric compounds that did not display protean
agonism showed increased Emax values, and all orthosteric
agonists gained binding affinity and potency in Tris compared
with Tris NaCl buffer, as agonists prefer binding to an active
rather than an inactive receptor (De Lean et al., 1980). The
classic muscarinic partial agonist pilocarpine is an exception to
this behavior as the compound changed neither in potency nor
in efficacy depending on the buffer composition. A previous
work (Tota and Schimerlik, 1990) reported that pilocarpine
does not distinguish between active and inactive receptors.
However, direct labeling of active M2 receptors with a radio-
agonist indicated higher apparent affinity of pilocarpine for this
receptor population in comparison with inactive receptors,
albeit the affinity difference was lower than the respective
difference for full agonists (Schrage et al., 2014). Together with
the finding that pilocarpine activates M2 receptors in native
tissue as well as in recombinant cells (Seemann et al., 2017),
this implicates that pilocarpine has higher affinity for the active
M2 receptor relative to the inactive form, although the nominal
difference in affinity appears to be lower than for full agonists.
On the whole, we established an experimental system that
allowed us to identify two new protean agonists at M2
muscarinic acetylcholine receptors. We propose an unprece-
dented molecular mechanism by which protean agonism is
induced at a class A GPCR, that is, the M2AChR, which may
virtually be extended to generate protean agonists for other
class A GPCRs harboring allosteric binding sites, such as
adenosine or dopamine receptors. It will be interesting to see
whether this dualsteric approach will furnish protean ligands
for other receptor types.
Similar to the great potential of biased GPCR signaling,
improved understanding of protean agonism may provide
another level toward the targeted exploitation of the GPCR
signalingmachinery, which could be relevant to the knowledge-
based design of innovative drug candidates.
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